Wells Fargo lowered the firm’s price target on Ascendis Pharma to $264 from $277 and keeps an Overweight rating on the shares. Q2 updates were messy, but Yorvipath’s U.S. commercial opportunity in HypoPTH and optionality for TransCon CNP support the firm’s thesis. Wells says it would buy on the weakness.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND: